October 7, 2024 Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney Portfolio Company News Read more
October 2, 2024 With $115M more, Triveni accelerates immune drug work Portfolio Company News Read more
October 1, 2024 Ron Renaud’s new obesity biotech, Kailera, has $400M to go straight to Phase 3 Portfolio Company News Read more
September 26, 2024 Endpoints 11 winner Lifordi Immunotherapeutics: Using antibodies to deliver potent steroids directly to immune cells Portfolio Company News Read more